BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 01/07/2016

FDA Announces Public Workshop on Erythropoietic Protoporphyria to Discuss Potential Drug Therapies

The FDA is hosting a public workshop to gather input from patients, healthcare providers, and industry experts on developing safe and effective treatments for Erythropoietic Protoporphyria, a condition that affects daily life, and to discuss the clinical development of potential therapies.

Source: Federal Register — Food and Drug AdministrationOpen original release →